{"id":"fudr-oxaliplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FUDR is a fluoropyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting nucleotide synthesis. Oxaliplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication and transcription. Together, they provide synergistic cytotoxic effects against colorectal and other solid tumors.","oneSentence":"FUDR (floxuridine) and oxaliplatin work together as a chemotherapy combination to inhibit DNA synthesis and cross-link DNA, killing rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:34.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (metastatic or locally advanced)"},{"name":"Hepatic arterial infusion chemotherapy for hepatic metastases"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT03693807","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-10-18","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":35},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT05634720","phase":"PHASE4","title":"Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2024-01-02","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT03366155","phase":"PHASE2","title":"Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-24","conditions":"Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma","enrollment":24},{"nctId":"NCT04891289","phase":"PHASE2","title":"Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-07","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":164},{"nctId":"NCT00492999","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-05","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":64},{"nctId":"NCT04251715","phase":"PHASE2","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-04-28","conditions":"Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","enrollment":5},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":38},{"nctId":"NCT00200200","phase":"PHASE2","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-11-19","conditions":"Hepatic Metastases, Colon Cancer, Rectal Cancer","enrollment":73},{"nctId":"NCT01862315","phase":"PHASE2","title":"Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma","enrollment":55},{"nctId":"NCT02102789","phase":"PHASE3","title":"A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Yuhong Li","startDate":"2014-03","conditions":"Metastatic Colorectal Cancer","enrollment":142},{"nctId":"NCT03500874","phase":"PHASE3","title":"Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2018-05-28","conditions":"Colorectal Cancer, Liver Metastases, HAI","enrollment":92},{"nctId":"NCT04276090","phase":"NA","title":"Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Michael J Cavnar, MD","startDate":"2020-05-01","conditions":"Bile Duct Neoplasms, Colorectal Neoplasms","enrollment":21},{"nctId":"NCT03678428","phase":"PHASE3","title":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2021-12-31","conditions":"Metastatic Colorectal Cancer, Liver Metastases","enrollment":92},{"nctId":"NCT03493061","phase":"PHASE2","title":"A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-02-01","conditions":"Colo-rectal Cancer, Liver Metastases","enrollment":60},{"nctId":"NCT01525069","phase":"PHASE1","title":"Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-04-03","conditions":"Cholangiocarcinoma, Liver Neoplasms","enrollment":27},{"nctId":"NCT00695201","phase":"PHASE1","title":"Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":"Colon Cancer, Rectal Cancer","enrollment":52},{"nctId":"NCT04668976","phase":"PHASE2","title":"A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Benaroya Research Institute","startDate":"2020-11-25","conditions":"Colorectal Cancer, Cholangiocarcinoma","enrollment":100},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04552093","phase":"PHASE2, PHASE3","title":"Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2020-09-09","conditions":"Colorectal Neoplasms","enrollment":31},{"nctId":"NCT01042691","phase":"PHASE1","title":"Isolated Liver Perfusion With Oxaliplatin","status":"COMPLETED","sponsor":"David Bartlett","startDate":"2003-05","conditions":"Unresectable Colorectal Liver Metastases","enrollment":10},{"nctId":"NCT00448760","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-10","conditions":"Esophageal Cancer","enrollment":29},{"nctId":"NCT00448682","phase":"PHASE2","title":"Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery","status":"TERMINATED","sponsor":"University of Miami","startDate":"2005-06","conditions":"Gastric Cancer","enrollment":25},{"nctId":"NCT00557557","phase":"PHASE1","title":"Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"David Bartlett","startDate":"2007-07","conditions":"Colorectal Liver Metastases","enrollment":14},{"nctId":"NCT02529774","phase":"PHASE2, PHASE3","title":"Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"Ye Xu","startDate":"2015-09","conditions":"Resected Liver Metastases From Colorectal Cancer","enrollment":432},{"nctId":"NCT02402972","phase":"PHASE3","title":"A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer","status":"UNKNOWN","sponsor":"Xu jianmin","startDate":"2015-02","conditions":"Colorectal Cancer, Metastasis","enrollment":700},{"nctId":"NCT00408551","phase":"PHASE2","title":"Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver","status":"UNKNOWN","sponsor":"Goshen Health System","startDate":"2005-11","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":20},{"nctId":"NCT00026234","phase":"PHASE2","title":"Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-02","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases","enrollment":75},{"nctId":"NCT00268463","phase":"PHASE3","title":"Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2006-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":22},{"nctId":"NCT00008294","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-08","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":""},{"nctId":"NCT00005860","phase":"PHASE1","title":"Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2000-04","conditions":"Cancer","enrollment":""},{"nctId":"NCT00874406","phase":"PHASE4","title":"Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-01","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT00869271","phase":"PHASE4","title":"Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2005-01","conditions":"Unresectable Liver Metastasis of Colorectal Cancer","enrollment":200},{"nctId":"NCT00868569","phase":"PHASE4","title":"Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-01","conditions":"Liver Metastasis, Colorectal Cancer","enrollment":200},{"nctId":"NCT00643877","phase":"PHASE3","title":"Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2008-12","conditions":"Colorectal Neoplasms","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["fluorodeoxyuridine (FUDR)"],"phase":"phase_3","status":"active","brandName":"FUDR +oxaliplatin","genericName":"FUDR +oxaliplatin","companyName":"Xu jianmin","companyId":"xu-jianmin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FUDR (floxuridine) and oxaliplatin work together as a chemotherapy combination to inhibit DNA synthesis and cross-link DNA, killing rapidly dividing cancer cells. Used for Colorectal cancer (metastatic or locally advanced), Hepatic arterial infusion chemotherapy for hepatic metastases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}